IGC Pharma, Inc.
IGC
$0.3262
$0.01986.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.64% | -11.98% | -15.38% | 47.48% | 40.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.64% | -11.98% | -15.38% | 47.48% | 40.09% |
| Cost of Revenue | 1.52% | -30.93% | -39.86% | 30.21% | 40.38% |
| Gross Profit | 1.76% | 11.95% | 15.50% | 65.84% | 39.82% |
| SG&A Expenses | -32.59% | -14.09% | -14.52% | -13.96% | -5.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.68% | -9.32% | -3.68% | -6.02% | -8.02% |
| Operating Income | 24.10% | 9.00% | 2.35% | 10.18% | 11.17% |
| Income Before Tax | 37.72% | -16.33% | -23.22% | -12.98% | -1.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.72% | -16.33% | -23.22% | -12.98% | -1.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.72% | -16.33% | -23.22% | -12.98% | -1.19% |
| EBIT | 24.10% | 9.00% | 2.35% | 10.18% | 11.17% |
| EBITDA | 25.47% | 9.48% | 2.44% | 10.61% | 11.43% |
| EPS Basic | 50.04% | 7.21% | -3.04% | 1.05% | 8.43% |
| Normalized Basic EPS | 40.45% | 27.91% | 17.47% | 20.26% | 18.21% |
| EPS Diluted | 50.04% | 7.21% | -3.04% | 1.05% | 8.43% |
| Normalized Diluted EPS | 40.45% | 27.91% | 17.47% | 20.26% | 18.21% |
| Average Basic Shares Outstanding | 29.68% | 29.64% | 20.66% | 12.10% | 7.82% |
| Average Diluted Shares Outstanding | 29.68% | 29.64% | 20.66% | 12.10% | 7.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
